Revolutionizing Disease Diagnosis and Treatment: Adaptive Biotechnologies Hosts Business Update Conference Call

Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Scheduled for April 2, 2024

Adaptive Biotechnologies Corporation, a biotechnology company listed on the Nasdaq under the ticker symbol ADPT, is dedicated to harnessing the biology of the adaptive immune system to revolutionize disease diagnosis and treatment. The company’s focus is on translating the genetics of the adaptive immune system into clinical products for these purposes.

To keep investors informed about its progress, Adaptive Biotechnologies has announced that it will be hosting a business update conference call and webcast on Tuesday, April 2, 2024, after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The live audio of the webcast will be available on the “Investors” section of the company website at Additionally, the webcast will be archived for replay within 24 hours after the event for those who could not make it to listen to it live.

Adaptive Biotechnologies believes that decoding the genetics of the adaptive immune system is a powerful tool for diagnosing and treating most diseases but has not been fully utilized due to its challenges. The company’s immune medicine platform enables this decoding with scale, precision, and speed, allowing it to collaborate with biopharmaceutical companies and inform drug development in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products and pipeline aid in diagnosing, monitoring, and treating diseases such as cancer, autoimmune disorders, and infectious diseases with a goal of developing personalized immune-driven clinical products for each patient.

For inquiries from investors related to this event or general information about Adaptive Biotechnologies’ operations or financial performance, Karina Calzadilla can be reached at For media inquiries about this event or other topics related to Adaptive Biotechnologies’ work in biomedical research or innovation, Erica Jones can be reached at

Leave a Reply